N
Overview
Nimbus is a mobile ad platform focused on helping publishers monetize their apps with efficiency and control. It uses intelligent auction design and real-time bidding from premium demand sources so each ad impression yields the best available price while preserving a smooth user experience. The platform distinguishes itself through transparent competition and a clear auction process, aiming to maximize publisher revenue without compromising ad quality or performance. Nimbus’s goal is to give publishers reliable, value-driven monetization that aligns with user experience and market value.
Work here?Claim your company
Simplify's take
What believers are saying
- November 2026 financing brought Nimbus $210 million from GV, SR One, and Atlas Venture.
- April 16, 2026 Takeda paid $4 billion for Nimbus's TYK2 program, validating the platform.
- November 5, 2026 ACR data presentation on selective SIK2 inhibition expands autoimmune visibility.
What critics are saying
- WRN Phase 1/2 and SIK2 first-in-human timelines keep clinical risk concentrated through 2027.
- Nimbus has a history of repeated financings; commercial revenue remains absent in 2026.
- If NDI-219216 or SIK2 fail, Nimbus loses its next value inflection and partnering leverage.
What makes Nimbus unique
- Nimbus Therapeutics uses structure-based design and AI chemistry to build small-molecule drugs.
- October 13, 2026 leadership additions deepen biology, chemistry, and business development.
- Its WRN inhibitor and SIK2 programs target difficult, high-value oncology and inflammation biology.
Help us improve and share your feedback! Did you find this helpful?